Synoposis
Friday MARCH 17, 2006
Time Session Title
7:30 AM Breakfast
8:15 AM The NSF SBIR matching grant program
Speaker/
Discussants		 T James Rudd Format: presentation
Focus and objective: The National Science Foundation - the very first federal agency to have instituted in 1977 what became the pilot for SBIR program - has launched an effort to encourage and support external investment in their awardees. Designated SBIR Phase IIB, NSF will match a third-party investment in the NSF funded project to a maximum of $500K. This session will look at the detail of how this works.
8:30 AM Okay ... you've made it to having the VC Term Sheet in your hands. What do all those clauses mean?
Speaker/
Discussants		 Richard N. Kimball, Nutter, McLennen & Fish, LLP
Alex Glovsky, Nutter, McLennen & Fish, LLP

 Format:Interactive Team session
Focus and objective: Involving two highly experienced VC attorneys, this session will systematically examine some of the language which will almost certainly be in the Term Sheet prepared by your Venture Capitalist. Topics to be addressed will include
  • Typical deal structures
  • Shareholder/Investor Rights Agreements
  • Governance and control issues
  • Architecture of the Equity - Anti-dilution protection; Pre-emptive rights; Redemption rights and Registration rights
  • Equity compensation issues
  • What to Anticipate in Negotiations.
9:10 AM Corporate Venture Capital: Myth, Mystery & Fact
Speaker/
Discussants		 Adam Caper, Synchrony Venture Management
Matthew Insley Growney, Motorola Ventures		 Format:Interactive working session
Focus and objective: Corporate Venture Capital has enjoyed a recent resurgence as the innovation landscape has flattened and become more open. CVC investment can offer a small firm the opportunity to build close ties with a valuable business partner, send a strong validating signal to the marketplace, and provide access to resources and complementary assets that it would never be able to generate on its own.
     But CVC investors have different requirements, processes and tempos than do financial venture capital investors, as well as an agenda that's a function of their company's core strategy. For companies considering whether to pursue financing options with CVCs, it pays to get a look at the world from their perspective.
     In this session, two CVC professionals will examine the role that CVC can play in helping companies succeed, and will share their perspectives to help you know what to expect when dealing with a potential corporate investor
9:45 AM Preparing the IP portfolio for your First (or Next) Round of Funding.
Speaker/
Discussants		 Ronald E Cahill, Nutter, McLennen & Fish, LLP Format: Analytical presentation
Focus and objective: A critical factor both in raising external capital at all and in setting a valuation on that funding is grounded in the strength and effectiveness of firm's Intellectual Assets portfolio. If you don't own it, you can't trade with it, sell it or raise money with it. Far more than simply a mechanisms for protection, the bedrock of your growth strategy and business development options is how what what you own is defined.
    This very focused session will effectively go through the process of a VC Audit of IP related issues.
10:05AM Refreshment Break
10:20 AM Concurrent Mini Plenaries
In these concurrent sessions, the SBIR Awardees selected for presentation are featured. Based on their applications, Presenting Firms have been allocated into one of two groupings.
  • Full Presentation: those SBIR Awardees - several already VC-funded at some level - which, based on received applications, judged ready to discuss the investment opportunity they represent.
  • Early-Stage firms: those SBIR Awardees - usually somewhat younger and smaller - which, based on received applications, were judged to have good potential but are not there yet. They are probably not ready fully to strut their stuff in pitch format. This very interesting group of companies will make shorter presentations seeking feedback and input in what is designed to be more of a workshop environment.
Event-registered Venture Capitalists have had Pre-Event access to the one-two page Nutshells on all Presenters that are in all Event Packages. For Full-Presenting firms, the participating VCs have also had Pre-Event access to the more detailed, 8-10 page Executive Summaries submitted by these more mature firms.
Full-Presentation Firms: Morning-THREE groupings

In each morning session, FIVE selected fi rms have been allocated a total of TWENTY-FIVE minutes each. Approximate start-time for each Presenter is indicated. Brief transition period is built in.

Each firm may use this time in whatever manner they choose. However, time allocations will be strictly enforced.
Primary Presentations:
FIVE featured firms each allocated a 25 minute slot Full-Presentation Session ONE:
Location: George Washington Carver Room 202

10:20 AM Moderator remarks: J. James Rudd, National Science Foundation, Arlington , VA

  • 10:25 AM Aonex Technologies Inc, Pasadena, CA; Robert G. L. Shorr, Presenter
  • 10:52 AM Versatilis LLC, Shelburne, VT; George Powch, Presenter
  • 11:20 AM Wang Electro-Opto Corporation, Marietta, GA; Johnson Wang, Presenter
  • 11:48 AM TPL Micropower Technologies, Albuquerque, NM; Charles Lakeman, Presenter
  • 12:15 PM Tailored Materials Corporation, Tucson, AZ; Charles Hassen, Presenter
Primary Presentations:
FIVE featured firms each allocated a 25 minute slot. Full-Presentation Session TWO::
Location: George Washington Room 302 (Third Floor)

10:20 AM Moderator remarks: Gregory Milman, NIAID, National Institutes of Health, Bethesda, MD

  • 10:25 AM Cornerstone Pharmaceuticals Inc, New York, NY; Rob Shorr, Presenter
  • 10:52 AM Nobex Corporation, Research Triangle Park, NC; Kenneth James, Presenter
  • 11:20 AM INCELL Corporation LLC, San Antonio, TX; Mary Pat Moyer, Presenter
  • 11:48 AM EP Limited, Somerville, MA; Michael Curley, Presenter
  • 12:15 PM Nanocopoeia Inc, St. Paul, MN; Karen M. Arnold, Presenter
Primary Presentations:
FIVE featured firms each allocated a 25 minute slot. Full-Presentation Session THREE::
Location: Library (Third Floor)

10:20 AM Moderator remarks: Robert J. Crowley, Massachusetts Technology Development Corporation, Boston, MA

  • 10:25 AM Biomedical Research Models, Inc., Worcester, MA; Dennis Guberski, Presenter
  • 10:52 AM Kinetic Muscles, Inc, Tempe, AZ; Ed Koeneman, Presenter
  • 11:20 AM Cambria Biosciences LLC, Woburn, MA; Leo Liu, Presenter
  • 11:48 AM Amyxa Pharmaceuticals, Woburn, MA; Trevor Castor, Presenter
  • 12:15 PM Argus Medical, Inc, Bethesda, MD; Alfredo Zarate, Presenter
Roundtable Start-Up Clinic A
Location: John Hancock Room 201:
With particular emphasis on the range of issues associated to the start-up, early-stage condition, by design this session is somewhat less tightly structured than full-blown presentation sessions in the time period.
Each selected fi rm is assigned up to TWENTY minutes to make presentation, take questions and receive relevant feedback from the various funding sources and other professionals experienced in the start-up and early-stage condition. Again, the time allocation will be enforced and each presenter may use their time as they see fit.

In this context, however, the Session Moderator and other professionals in the room have more fl exibility about how they run the session. Order of presentation will be retained but the amount of time between presentations may be longer with the balance of time used for working discussion of the common issues raised by the case presentations.

10:30 AM Moderator remarks: Lawrence S. Nannis, Levine, Katz, Nannis & Solomon, PC, Needham, MA

Presenting Firms:
  • Intelligent Automation, Inc, Rockville, MD; Eric van Doorn, Presenter
  • Prodyne Corporation, Newton, MA; Steven Africk, Presenter Af
  • CostVision Inc., Boulder, CO; Charlie Stirk, Presenter
  • Chromis Fiberoptics LLC, Warren, NJ; Whitney White, Presenter
  • Freight Pipeline Company, Columbia, MO; Henry Liu, Presenter

12:45 PM Luncheon: Robert E. Perry Room 303
  The Future of Venture Capital
Speaker/
Discussants		 Josh Lerner, Harvard Business School Format: Post Luncheon presentation
Featuring a well-known analyst of the VC condition inthe US and elsewhere, this talk will examine the current venture capital environment. The speaker will discuss his assessment of the likely future of the industry. He will argue that the most dramatic changes are in the “upstream” side - with important consequences for the entrepreneur.
2:00 PM Concurrent Mini Plenaries
Primary Presentations:
FOUR featured firms each allocated a 25 minute slot Full-Presentation Session FOUR:
Location: John Hancock Room 201

2:00 PM Moderator remarks: Robert J. Crowley, Massachusetts Technology Development Corporation, Boston, MA

  • 2:03 PM ComSense Technology Inc, Cleveland, OH; Robert Schmidt, Presenter
  • 2:30 PM Gibbard Research and Development Corporation, Haverhill MA; H. Frank Gibbard, Presenter
  • 3:00 PM Vista Engineering Inc, Birmingham, AL; Raymond Thompson, Presenter
  • 3:30 PM Zweave Inc, Boston, MA; David Buck, Presenter
Primary Presentations:
FOUR featured firms each allocated a 25 minute slot. Full-Presentation Session FIVE::
Location: George Washington Carver Room 202

2:00 PM Moderator remarks: Lawrence S. Nannis, Levine, Katz, Nannis & Solomon, PC, Needham, MA

  • 2:03 PM Guardian Solutions Inc, Bradenton, FL; John Montelione, Presenter
  • 2:30 PM RemoteReality Corporation, Westborough MA; Mike Zwolinski, Presenter
  • 3:00 PM ImTelligenceŽ Inc, East Hartford, CT; Keith R. Reynolds, Presenter
  • 3:30 PM Securics Inc, Colorado Springs, CO; Terrance Boult, Presenter
Primary Presentations:
FOUR featured firms each allocated a 25 minute slot. Full-Presentation Session SIX::
Location: George Washington Room 302 (Third Floor)

2:00 PM Moderator remarks: J. James Rudd, National Science Foundation, Arlington, VA

  • 2:03 PM Microvi Biotech LLC, Overland Park, KS; Wil Jacques, Presenter
  • 2:30 PM CryoFacets, Inc., Raleigh, NC; Howard Purdum, Presenter
  • 3:00 PM Phylogenetix Laboratories Inc., Overland Park, KS; Ronan Molloy, Presenter
  • 3:30 PM Biosomes, Inc, Wilmington, DE; Charles Saller, Presenter
Roundtable Start-Up Clinic B
Location: Library Third Floor:
With particular emphasis on the range of issues associated to the start-up, early-stage condition, by design this session is somewhat less tightly structured than the other full-blown presentation sessions in the time period.
Each selected fi rm is assigned up to TWENTY minutes to make presentation, take questions and receive relevant feedback from the various funding sources and other professionals experienced in the start-up and early-stage condition. Again, the time allocation will be enforced and each presenter may use their time as they see fit.
In this context, however, the Session Moderator and other professionals in the room have more fl exibility about how they run the session. Order of presentation will be retained but the amount of time between presentations may be longer with the balance of time used for working discussion of the common issues raised by the case presentations.

2:00 AM Moderator remarks: Aaron Sandoski, Norwich Ventures, Cambridge, MA

Presenting Firms:
  • AVANCEN, LLC, Ormond Beach, FL; Ned Buffington, Presenter
  • EMTAC Inc,Santa Barbara, CA; Russell Rising, Presenter
  • ThromboVision Inc., Houston, TX; Edward Teitel, Presenter
  • Gene Regulation Laboratories, Newton, MA; Susan P Perrine, Presenter

4:00 PM Let me ask you this: an interactive Q/A
involving several of the participating professionals
4:30 PM Conference Concludes
Networking reception